1. Home
  2. HRMY vs POET Comparison

HRMY vs POET Comparison

Compare HRMY & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$32.44

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo POET Technologies Inc.

POET

POET Technologies Inc.

SELL

Current Price

$7.15

Market Cap

1.6B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
HRMY
POET
Founded
2017
1972
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
HRMY
POET
Price
$32.44
$7.15
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$44.11
N/A
AVG Volume (30 Days)
799.5K
35.7M
Earning Date
05-07-2026
08-12-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
N/A
Revenue
$868,453,000.00
N/A
Revenue This Year
$19.75
$848.96
Revenue Next Year
$12.88
$700.00
P/E Ratio
$11.72
N/A
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$3.87
52 Week High
$40.87
$15.50

Technical Indicators

Market Signals
Indicator
HRMY
POET
Relative Strength Index (RSI) 66.25 47.28
Support Level $32.13 $5.40
Resistance Level $33.21 $9.14
Average True Range (ATR) 1.32 1.42
MACD 0.19 -0.34
Stochastic Oscillator 58.88 8.11

Price Performance

Historical Comparison
HRMY
POET

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About POET POET Technologies Inc.

POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.

Share on Social Networks: